Acesso livre
Acesso livre

Arquivos do dia: Setembro 20, 2021

Relatório do CDC | Vacina da Moderna está associada a alta efetividade (93%) contra hospitalização por Covid-19 em comparação às vacinas da Pfizer (88%) e da J&J (71%).

20 Set, 2021 | 13:59h

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 – CDC Morbidity and Mortality Weekly Report

Comentários:

Moderna’s vaccine is the most effective, but Pfizer and J&J also protect well, CDC-led study says – CNN

CDC: Moderna COVID vaccine most protective against hospital cases – CIDRAP

CDC data: Moderna vaccine has edge in preventing COVID-19 hospitalizations – UPI

 

Comentário no Twitter

 

Revisão | Sintomas de “long COVID” em crianças raramente persistem por mais de 3 meses.

20 Set, 2021 | 13:57h

Comunicado de imprensa: Long COVID symptoms in children rarely persist beyond three months –  Murdoch Children’s Research Institute

Estudo original: How Common Is Long COVID in Children and Adolescents? – The Pediatric Infectious Disease Journal

Comentário: Long Covid in children and adolescents is less common than previously feared – The Guardian

Conteúdos relacionados:

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Long COVID: the physical and mental health of children and non-hospitalized young people after SARS-CoV-2 infection – one in seven children may still have symptoms 15 weeks after infection.

Do kids get long COVID? And how often? A pediatrician looks at the data – Children also get Long Covid, but much less often than adults.

Illness duration and symptom profile in symptomatic school-aged children tested for SARS-CoV-2 – “Only 25 (1.8%) of 1379 children experienced symptoms for at least 56 days.”

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease

Cohort study: Risk factors for long covid in previously hospitalized children.

M-A: More than 50 long-term effects of COVID-19.

 

Comentário no Twitter (fio – clique para saber mais)

 

Um painel da FDA afirma que somente americanos de alto risco e os maiores de 65 anos deveriam tomar as doses de reforço contra Covid.

20 Set, 2021 | 13:56h

An FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR

Ver também:

FDA advisory panel recommends booster doses of Covid-19 vaccine only for older and high-risk Americans – STAT

5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN

Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press

Conteúdos relacionados:

An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

Third shot: UK to offer COVID booster jabs to over 50s.

COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

COVID vaccine effects wane over time but still prevent death and severe illness.

What’s the evidence for COVID-19 booster shots?

WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.

Todos precisam de dose de reforço? – “Por que algumas pessoas poderiam precisar de uma dose de reforço de vacina contra Covid-19 – e outras, não.”

20 Set, 2021 | 13:54h

Does everybody need a booster shot? – Vox

Opinião | Vacinar o mundo antes de começar as doses de reforço contra COVID – “Menos de 0,5% das doses de vacina foram distribuídas a pessoas de países de baixa renda.”

20 Set, 2021 | 13:53h

Vaccinate the World before Starting COVID Booster Shots – Scientific American

Conteúdo relacionado: WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

Imunidade conferida pela vacina contra COVID está caindo: o quanto isso importa? – “Enquanto os debates sobre as doses de reforço se acirram, o que se sabe sobre a duração da imunidade baseada em vacina ainda está em evolução.”

20 Set, 2021 | 13:51h

COVID vaccine immunity is waning — how much does that matter? – Nature

OMS/ILO | Quase 2 milhões de pessoas morrem de causas relacionadas a trabalho a cada ano.

20 Set, 2021 | 13:50h

Comunicado de imprensa: WHO/ILO: Almost 2 million people die from work-related causes each year – World Health Organization

Relatório: WHO/ILO joint estimates of the work-related burden of disease and injury, 2000-2016: global monitoring report – World Health Organization

 

Comentário no Twitter

 

Doença hepática gordurosa não alcoólica: uma diretriz para o paciente.

20 Set, 2021 | 13:48h

Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports

 

Comentário no Twitter

 

Amplo estudo de coorte sugere que a substituição de rotina de cateteres intravenosos periféricos (a cada 96 horas) pode reduzir o risco de infecções sanguíneas em comparação à substituição indicada clinicamente.

20 Set, 2021 | 13:47h

Comparison of Routine Replacement With Clinically Indicated Replacement of Peripheral Intravenous Catheters – JAMA Internal Medicine (gratuito por tempo limitado)

Revisão Cochrane relacionada, com diferentes achados: Systematic Review: Clinically‐indicated vs. Routine Replacement of Peripheral Venous Catheters

 

Comentário no Twitter

 

Efeitos adversos em um estudo comparando estatina, placebo e nenhum tratamento – Este estudo N-de-1, agora publicado na totalidade, sugere que o efeito de “nocebo” causa a maioria dos efeitos adversos musculares das estatinas.

20 Set, 2021 | 13:45h

Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment – Journal of the American College of Cardiology

Ver também: #AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.